Stocks
GlaxoSmithKline (GSK) EBITDA margin US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | 5 years average | |||
| EBITDA margin, % | ? | 26.3% | 29.3% | 29.9% | 21.3% | 31.8% | 34.4% | ||
| Changes by years, y/y, % | -7pp | +3pp | +1pp | -9pp | +11pp | 28% | |||
GlaxoSmithKline. EBITDA margin, %
GlaxoSmithKline. EBITDA margin, changes, pp
GlaxoSmithKline (GSK) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2025Q4 | FY2025Q4 | FY2026Q1 | FY2026Q2 | FY2026Q2 | LTM ? | |||
| EBITDA margin, % | ? | 22.1% | 22.1% | 36.4% | 33.6% | 33.6% | 34.4% | |
| Changes by years, y/y, % | +8pp | +8pp | -5pp | -7pp | -7pp | |||
| Changes by quarters, q/q, % | -17pp | 0pp | +14pp | -3pp | 0pp | |||
